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Abstract: The human milk microbiota is a complex and diverse ecosystem that seems to play a
relevant role in the mother-to-infant transmission of microorganisms during early life. Bacteria
present in human milk may arise from different sources, and recent studies suggest that at least
some of them may be originally present in the maternal digestive tract and may reach the mammary
gland through an endogenous route during pregnancy and lactation. The objective of this work was
to elucidate whether some lactic acid bacteria are able to translocate and colonize the mammary
gland and milk. For this purpose, two lactic acid bacteria strains (Lactococcus lactis MG1614 and
Lactobacillus salivarius PS2) were transformed with a plasmid containing the lux genes; subsequently,
the transformed strains were orally administered to pregnant mice. The murine model allowed the
visualization, isolation, and Polymerase Chain Reaction (PCR)-detection of the transformed bacteria
in different body locations, including mammary tissue and milk, reinforcing the hypothesis that
physiological translocation of maternal bacteria during pregnancy and lactation may contribute to
the composition of the mammary and milk microbiota.
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1. Introduction
Human milk contains microorganisms that, together with other milk components, play a pivotal
role in the early colonization of the infant gut. The use of diverse culture-dependent or-independent
techniques has allowed either the isolation or detection of a wide spectrum of commensal bacteria in
milk samples provided by healthy women worldwide [1]. Most research efforts have been focused on
lactobacilli and bifidobacterial isolates because of their potential to be used as probiotics [2].
Traditionally, the presence of bacteria in human milk was related to contamination from the
mother’s skin or infant’s oral cavity [2]. In addition, bacterial translocation from the digestive tract
of healthy women has been proposed as a source of bacteria for the mammary gland during late
pregnancy and lactation [3]. In fact, physiological translocation of commensal bacteria from the gut to
different mucosal surfaces has already been shown in vitro and in vivo through a mechanism involving
complex interactions between bacteria, epithelial cells, and immune cells (including dendritic cells
and macrophages) [3,4]. Previous studies have reported that oral administration of some lactobacilli
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strains to lactating women leads to their presence in milk [5,6]. However, more mechanistic studies
focused on the potential bacterial transfer from the gut to the mammary glands of healthy hosts are
required to further confirm such findings.
Bioluminescent whole-body imaging allows rapid and real-time monitoring of bacteria in vivo.
This system captures photons of light emitted by naturally luminescent bacteria or by those that have
been genetically manipulated to produce bioluminescence. The bioluminescence reaction involves a
luciferase-catalyzed intracellular oxidation of a long-chain fatty aldehyde (R-CHO) together with a
concomitant reduction of flavin mononucleotide (FMNH2). Such reactions lead to the generation of
blue-green light, as follows: FMNH2 + O2 + R-CHO→ FMN + H2O + R-COOH + Light (~495 nm).
The lux operon (luxABCDE) contains the genetic determinants for bioluminescence and includes the
structural genes (luxA and luxB) coding for the two subunits (α and β, respectively) of the luciferase
enzyme as well as three additional genes (luxC, luxD, and luxE) encoding the fatty acid reductase
complex responsible for fatty aldehyde synthesis [7].
Bioluminescence imaging has successfully demonstrated in vivo translocation of pathogenic
strains of Escherichia coli and Citrobacter rodentium in mice [8–10], and persistence of Lactococcus lactis
and Lactobacillus plantarum strains in the murine gastrointestinal tract [11]. In addition, translocation of
bioluminescent bifidobacteria from the gastrointestinal tract of mice, and their subsequent selective
recruitment by tumoral cells, have been shown using such an approach [12]. In this context, the
objective of this work was to obtain bioluminescent lactic acid bacteria (LAB) strains to provide in vivo
evidence of their physiological translocation in mice during late pregnancy and lactation.
2. Material and Methods
2.1. Bacterial Strains and Media
The LAB strains used in this work as recipients for the lux genes were LactococcuslactisMG1614,
a laboratorial strain widely used in studies dealing with molecular biology of lactococci [13],
and Lactobacillus salivarius PS2, a probiotic strain originally isolated from human milk [14–16].
L. lactisMG1614 was routinely grown in M17 (Oxoid, Basingstoke, UK) supplemented with 0.5%
(w/v) glucose (GM17 medium) and incubated at 30 ◦C, while L. salivariusPS2 was grown in Man,
Rogosa, and Sharpe (MRS) (Oxoid) medium and incubated at 37 ◦C. Competent Escherichia coli cells
were purchased from Bioline (BIO-85027; Bioline Reagents Ltd., London, UK). E. coli was grown in
Luria Bertani (LB) medium and incubated at 37 ◦C. When required, erythromycin (Em) (Sigma-Aldrich,
St. Louis, MI, USA) was added to the cultures at the following concentrations: 150 µgmL−1 for E. coli,
2.5 µg mL−1 for L. lactisMG1614, and 5 µg mL−1 for L. salivarius PS2. Previously, the Em resistance
of L. salivarius PS2 had been tested in MRS broth containing Em concentrations ranging from 0.25 to
5 µg mL−1 at 37 ◦C for 24 h and bacterial growth was detected by measuring the OD600 of the cultures.
2.2. Construction of pMG36e::luxAB and pMG36e::luxABCDE
Plasmid pXen-5 (Xenogen Bioware, Alameda, CA, USA) was used as template to amplify the
luxABCDE operon using primers XAF1/XBR1 (which generate a DNA fragment containing only the
structural genes luxAB) and XAF1/XER2 (which generate a DNA fragment containing the complete
luxABCDE operon) [17]. However, primers XAF1/XBR1 were modified to add restriction sites
SacI/SmaI and SacI/SalI, respectively, at the ends of the amplicons (Table 1). PCR was performed using
Phusion Hot Start II DNA High-Fidelity DNA Polymerase (Finnzymes, Vantaa, Finland) with the
following conditions: 98 ◦C for 30 s; 35 cycles at 98 ◦C for 10 s, 72 ◦C for 1 min, 72 ◦C for 5 s; and finally,
72 ◦C for 5 min. PCR products were purified using Sure Clean Plus (Bioline, London, UK) following
the manufacturer’s instructions.
After digestion of the vector (plasmid pMG36e) with the corresponding enzymes (New England
Biolabs. SmaI, at 25 ◦C; SacI and SalI at 37 ◦C; all incubations occurred overnight), ligations were
performed overnight at 16 ◦C with T4 DNA ligase (Roche, Mannheim, Germany) to generate plasmids
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pMG36e::luxAB and pMG36e::luxABCDE, respectively. Plasmid pMG36e is a 3.6 kb expression
vector carrying an Em resistance gene and the strong P32 promoter [18]. Both plasmids were
separately introduced into competent cells of E. coli (BIO-85027; Bioline), following the manufacturer’s
instructions. Cells were plated on LB plates supplemented with Em (150 µg mL−1) in order to select
for transformants.
Table 1. Primers used in this study for the Polymerase Chain Reaction (PCR) detection of lux genes.
Name Sequence (5′-3′) Reference or Source
XAF1 CCC CGA GCT CAT GAA GCA AGA GGA GGA CTC TCT ATG Modified from [17]
XBR1 GGC CCC GGG TTA GGT ATA TTC CAT GTG GTA C Modified from [17]
XAF1 CCC CGA GCT CAT GAA GCA AGA GGA GGA CTC TCT ATG Modified from [17]
XER2 GGC GGC GTC GAC TTA ACT ATC AAA CGC TTC GGT TA Modified from [17]
lux1280 ACG CCG CAG GAA TGT ATT GA This study
lux1732 TAT GGC GAC AGG ATG ATG AG This study
lux4807 GTC AAT GAA CGC CGA ATG AG This study
lux5068 GTC ACT ACT GTC AGG CAC AC This study
2.3. Transformation of L. lactis MG1614 and L. salivarius PS2
Both plasmids were extracted from transformed E. coli cells using the Qiagen plasmid mini kit
(Qiagen, Hilden, Germany) and electroporated into L. lactisMG1614 cells as described previously [19].
After electroporation, L. lactis cells were plated on GM17 supplemented with Em (2.5 µg mL−1) and
incubated at 30 ◦C for 48 h. Subsequently, both plasmids (containing P32-luxAB and P32-luxABCDE,
respectively) were isolated from the previously transformed L. lactis MG1614 cells and electroporated
into competent L. salivariusPS2 cells, which had been obtained as previously described [20]. Then,
bacterial cells were plated on MRS plates supplemented with Em (5 µg mL−1) and incubated at
37 ◦C for 48 h. The stability of the recombinant plasmids was assayed by daily sub-culturing of the
recombinant strains in non-selective media during seven consecutive days. Aliquots of each subculture
were plated on selective (Em-supplemented MRS) and non-selective (MRS) agar plates [21]. Plasmid
maintenance was determined by comparing the numbers of colonies that grew on both types of media.
Presence of the plasmids in the transformant cells was confirmed by PCR. Primers
lux1280F/lux1732R allow the amplification of a 452 bp fragment located between luxA and luxB
genes, while primers lux4807F/lux5068R were designed to amplify a 261 bp fragment between luxD
and luxE genes (Table 1). PCR was performed using My Taq™ Red DNA Polymerase (Bioline) and
the following conditions: 94 ◦C for 4 min; 25 cycles at 94 ◦C for 30 s, 53 ◦C for 30 s, 72 ◦C for 30 s, and
72 ◦C for 5 min. The amplified fragments were visualized by electrophoresis in a 1.2% agarose gel after
90 min at 90 V.
2.4. Bioluminescence Assays
Bioluminescence assays were performed in collaboration with the Biolum Lab of the “Red de
Laboratorios de la Comunidad de Madrid”. Production of bioluminescence by the bacterial cultures
was measured directly in broth medium (1 mL) with a luminometer (Biocounter® M1500 Lumacbv,
Landgraaf, The Netherlands), and the bioluminescence was expressed as Relative Light Units (RLUs).
The presence of bioluminescent signals was also analyzed on the surface of agar plates using the IVIS
100 imaging system (In Vivo Imaging System, Xenogen, Perkin Elmer, Hopkinton, MA, USA), which
consists of a cooled charge-coupled-device (CCD) camera mounted on a light-tight specimen chamber.
The signal intensity was quantified as photon counts per second (p/s).
2.5. In Vivo Translocation Model
Ten-week-old pregnant Balb/c mice (Day 5 of gestation) were used to assess the potential in vivo
translocation of the transformed L. lactis and L. salivarius strains. Animals were kept in the Animal
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Facility of Centro de Biología Molecular Severo Ochoa (CBM-CSIC, Madrid, Spain), and housed
individually (one pregnant mouse per cage) in 1264C Eurostandard Type II cages (26.7 × 20.7 ×
14.0 cm-floor area 370 cm2, Tecniplast, Buguggiate, Italy) with bedding, food (Diet 2018, Harlan,
Correzzana, Italy) and water available ad libitum, under a temperature (22 ◦C) and light-controlled
(12 h) cycle. All experimental procedures complied to the principles of good laboratory animal care,
were carried out in compliance with national legislation following the EU-Directive 2010/63/EU for
the protection of animals used for scientific purposes, and were approved by the ethics committee for
animal experimentation and the Animal Welfare Body of CBM/Complutense University of Madrid,
Spain (Code 15/017E; approval date: January 2015). All adequate measures were taken to minimize
animal pain or discomfort.
Bacterial strains were grown overnight in GM17 supplemented with Em (2.5 µg mL−1) at 32 ◦C
(L. lactis cells) or MRS supplemented with Em (5 µg mL−1) at 37 ◦C (L. salivarius cells). Cells were
harvested by centrifugation (18,800× g for 10 min at 4 ◦C) and the pellet was resuspended in a mixture
of 10% skimmed milk with 10% of 2.5 M sucrose. The mix was dispensed as single-doses (200 µL,
~109 CFU/dose), lyophilized, and kept at −20 ◦C until their administration to mice. The stability of
the doses was assessed weekly by plate count on GM17 (Em: 2.5 µg mL−1) or MRS (Em: 5 µg mL−1)
agar plates.
Test mice (n = 6) received a daily dose (at the same time each day) of transformed L. lactis (n = 2)
or L. salivarius (n = 4; two pregnant and two non-pregnant females) intragastrically via oral gavage
until delivery (~20 days). Control mice (n = 5) received a daily dose (200 µL) of the probiotic matrix
(10% skimmed milk with 10% of 2.5 M sucrose) also by intragastric administration.
At Day 15 of pregnancy and within the first 6 h after delivery, in vivo bioluminescence imaging
of the mice was performed using the multimodal IVIS 100 imaging system described above. For
this purpose, mice were anesthetized with 2% isoflurane and placed into the camera chamber, where
a controlled flow of 1.5% isoflurane-supplemented air was administered through a gas anesthesia
system. Bioluminescence was quantified as p/s using the Living Image® software (Caliper Life
Sciences, Waltham, MA, USA).
Within the first 12 h after delivery, the female mice and their offspring (before weaning) were
euthanized using a mixture of CO2/O2 according to the EU guidelines and necropsies performed
under sterile conditions. Samples of feces, milk, urine, blood (EDTA tubes), and biopsies of intestine
(large and small), stomach, liver, spleen, kidneys, mammary glands, uterus, Peyer’s patches, and
mesenteric nodes were collected and stored at 4 ◦C for microbiological and microscopy-based analysis.
To evaluate potential translocation of the transformed strains from the gastrointestinal tract to
different tissues, the biological samples (biopsies, urine, milk, and feces) were homogenized in peptone
water (with the exception of urine and milk) and decimal serial dilutions were spread on selective
GM17 (Em: 2.5 µg mL−1) or MRS (Em: 5 µg mL−1) agar plates.
Tissue biopsies were fixed, processed, and analyzed by transmission electron microscopy (TEM)
as described previously [22]. For this purpose, blood was centrifuged (620× g for 20 min 4 ◦C), to
collect the cells and the pellet was embedded in an agarose matrix before fixing in paraformaldehyde
and glutaraldehyde.
2.6. Statistics Analysis: Sample Size Calculation
The recommended number of animals included in this trial was determined using the G*Power
3.1.9.2 program [23], and previous results obtained after oral administration of a genetically labeled
Enterococcus faecium strain to pregnant mice [24]. The minimum value for the frequency of detection of
the lux-labeled strain in the experimental group was estimated to be 80%, while it was not expected
to be found in the control group. The minimum sample size was estimated to be 12 animals, using
a 1:1 allocation ratio, and considering a one-tailed test, a 5% alpha level, and a statistical power of
90% to demonstrate a significant difference. Since one mouse in the control group was lost (a mouse
that did not become pregnant) and the real proportion of animals containing lux-labeled Lactococcus
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in the experimental group was higher than 80%, a post hoc analysis was performed. This analysis
confirmed that the achieved power was higher (>99%) than the value that had been selected initially
for the calculation.
3. Results
3.1. Transformation of E. coli and LAB Strains with pMG36e::luxAB and pMG36e::luxABCDE
Transformation of competent E. coli cells with plasmid pMG36e::luxAB or pMG36e::luxABCDE led
to bacterial grow in selective conditions. Some colonies showed bioluminescence both in broth
(RLU > 1500) and agar plates and, therefore, were selected for further studies (Figure 1). The
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Figure 1. Transformation of E. coli with the lux operon. (A) LB agar plate showing non-transformed E.
coli cells (negative control). (B) LB agar late showing E. coli cells transformed with pMG36e::luxABCDE.
(C) Micr titer plate showing E. coli cells transformed with pMG36e::luxABCDE; Column 1:
non-inoculated LB medium (negative control); Column 2: files b to f: serial dilutions of E. coli cells
transformed with pMG36e::luxABCDE.
Similarly, the successful transformation of L. lactis MG1614 with either pMG36e::luxAB
or pMG36e::luxABCDE and that of L. salivarius PS2 with pMG36e::luxAB was confirmed by
biolumin scence and PCR (Figure 2). However, the transformation of L. salivarius PS2 with
pMG36e::luxABCDE was n t possible af er several lectroporation att mpts. The ddition of D-luciferin
Firefly (Xenogen) to the growth medium (150 µg/mL) was required in order to generate and detect














homogenized  (when  required),  and  seeded  on  MRS  and  on  MRS  supplemented  with  Em 
(5 μg mL−1) agar plates. PCR analyses were also carried out to detect the presence of the luxAB genes 
in the biological samples. The counts obtained from the different samples analyzed in this study are 
shown  in Table  2. Bacterial  growth was  observed  in  the  fecal  samples  from  all  the  animals. As 
expected,  fecal  bacterial  counts  (expressed  as  cfu/g)  were  3–4  log10  cycles  higher  in  MRS 
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Figure 2. In vitro and in vivo detection of L. lactis MG1614 transformed with pMG36::luxABCDE.
(A) GM17 agar plate with transformed (left) and non-transformed (right) L. lactis MG1614 cells.
(B) Mouse immediately (left) and 20 min (right) after being fed with L. lactis pMG36e::luxABCDE.
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The stability of L. salivarius PS2 transformed with pMG36e::luxAB was measured during~100
generations under selective (Em-supplemented) and non-selective conditions. The growth of the
transformed strain in selective medium was ~1 log10 cycle higher in comparison to that observed in the
non-selective one. Such difference remained constant along time, indicating that recombinant plasmid
was stable in L. salivarius PS2.
3.2. In Vivo Translocation Model
A strong bioluminiscence signal was detected in the stomach of mice during the first 20 min
after oral administration of the transformed strains (Figure 2). The bacteria gradually entered (and
became diluted) in the gut compartment and, as a consequence, bioluminescence was lost ~1 h after
their administration.
In relation to recombinant L. lactis (pMG36::eluxABCDE), mice were sacrificed at the end of the
assay and biological samples (milk, urine, and feces) and biopsies of different organs and tissues were
collected, homogenized (when required), and seeded on plates of agar GM17 supplemented with Em
(2.5 µg mL−1). After incubation, bioluminescent L. lactis colonies could be isolated from the samples
of milk, urine, and feces and from the biopsies of mammary gland, liver, kidney, intestine, stomach,
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Figure 3. Isolation of transformed L. lactisMG161 lls on GM17 gar plates from different maternal
biological samples and organ biopsies: 1: milk; 2: feces; 3: small intestine; 4: large intestine; 5: kidney;
6: liver; 7: spleen; 8: stomach; 9: Peyer’s patch; 10: urine; and 11: mammary gland.
With respect to recombinant L. salivarius (pMG36::eluxAB), th four mice that received the strain
and one from the control group were sacrificed within one day after delivery. Feces and biopsies
from small intestine, cecum, mammary gland, spleen and mesenteric lymph nodes were collected,
homogenized (when required), and seeded on MRS and on MRS supplemented with Em(5 µg mL−1)
agar plates. PCR analyses were also carried out to detect the presence of the luxAB genes in the
biological samples. The counts obtained from the dif erent samples analyzed in this study are shown
in Table 2. Bacterial growth was observed in the fecal samples from all the animals. As expected, fecal
bacterial counts (expressed as cfu/g) were 3–4 log10 cycles higher in MRS (non-selective medium) than
in Em-supplemented MRS (selective medium) plates. The luxAB fragment could be detected by PCR
from feces of the four mice that received the reco binant strain but not from those collected from the
control animal. In addition, th str in could be isolated nd PCR-detected from mammary biopsies of
the pregnant mice but not from those collected from the non-pregnant ic . Ba terial counts in the
mammary samples were notably lower than fecal counts obtained from the same media and from the
same animal (Table 2).
The luxAB fragment could not be detected either in spleen or in mesenteric lymph node samples.
However, bacteria were observed in mesenteric lymph nodes (Figure 4A) and spleen (Figure 4B)
by TEM image analysis. Using such a technique, bacterial cells appeared as a double membrane
surrounding a dense content (chromatin) (Figure 4). Similar structures were detected in mammary
gland biopsies.
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Table 2. L. salivarius PS2 counts (log10 cfu/g) in the biological samples collected from mice (1 and 2:



































































Figure  4.  Transmission  electron  microscopy  (TEM)  images.  Bacteria  (black  arrows)  and 
mitochondria (white arrows) present in samples from a mesenteric lymph node (A) and spleen (B). 
  
Figure 4. Transmission electron microscopy (TEM) images. Bacteria (black arrows) and mitochondria
(white arrows) present in samples from a mesenteric lymph node (A) and spleen (B).
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4. Discussion
In this work, two LAB strains (L. lactis MG1614 and L. salivarius PS2) were genetically modified to
harbor genes belonging to the lux operon. This strain-labeling method constitutes an excellent tool
for in vivo whole-body detection of bacteria in animal models [25]. Its advantages include (a) a very
sensitive and rapid detection of luciferase activity, (b) a luminescent response that is linearly dependent
on the amount of luciferase, and (c) the possibility of using real-time non-invasive techniques when
combined with low-light imaging CCD cameras [25,26].
The recombinant plasmid pMG36e::luxABCDE was successfully transformed into L. lactis MG1614,
but it could not be successfully electroporated into L. salivarius PS2. The large size of the plasmid
(>10 kb) and the fact that L. salivarius PS2 is a wild strain may explain our inability to obtain
transformants. Fortunately, L. salivarius PS2 cells were transformed with the smaller pMG36e::luxAB
plasmid. In the absence of the luxCDE genes, strain-specific bioluminescence can still be detected
provided that D-luciferin is added to the growth medium.
Both strains could be isolated (and the lux genes detected by PCR) from either milk or mammary
gland biopsies after their oral administration to pregnant mice. While some may argue that their
presence in milk might be the result of superficial fecal contamination in mice, such a route can hardly
explain their isolation and detection from mammary biopsies. In a previous work, oral administration
of L. salivarius PS2 to pregnant women led to the presence of the strain in the milk of some of the
women after delivery [16]. It must be noted that, in contrast to mice, fecal contamination of human
milk is highly improbable and, in fact, enterobacteria are usually absent in milk samples collected by
manual expression from healthy women [27]. Our results reinforce the hypothesis that, at least, some
members of the milk microbiota may arise from the digestive tract of the mother.
In the last years, different studies have shown that milk from healthy women contain bacteria that
are subsequently transferred to the infant gut [1,28–36]. The detection of cells and/or DNA belonging
to anaerobic species that are related to the adult gut environment (Blautia, Bifidobacterium, Bacteroides,
Parabacteroides, Clostridium, Collinsella, Coprococcus, Faecalibacterium, Roseburia, Subdoligranulum, or
Veillonella) has ledtothe hypothesisthat some of the human milk bacteria may originate in the maternal
digestive tract (mouth, gastrointestinal tract) and reach the mammary gland through an endogenous
route [3,4,31,33,37].
So far, culture-independent studies have not provided information on microbial viability and
have not allowed strain level discrimination. A second caveat of molecular methods is the low amount
of DNA typically extracted from milk samples, making the relative proportion of contaminant DNA
from sample manipulation and from DNA extraction reagents more important than when analyzing
other biological samples, such as feces [33,38]. However, the role of breastfeeding in the vertical
mother-to-infant transfer of specific bacterial strains (including bifidobacteria and lactic acid bacteria
strains) has already been demonstrated [6,16,31,33–35,38–45]. Some studies have revealed the ability
of certain gut bacteria to spread to extra-digestive locations in healthy hosts [46–50], while others
(including in vitro, animal, and human studies) have shown that physiological bacterial translocation
during late pregnancy has a scientifically plausible basis and may involve complex interactions between
microbes, immune cells, and gut epithelial cells [4–6,16,47,51–56].
Gut bacteria translocation has usually been associated with pathogenic conditions [57–60], but
a low rate of bacterial translocation (involving Bacteroides, lactobacilli, bifidobacteria, or enterococci)
occurs in healthy hosts [12,60–66] and may be associated to physiological immunomodulation [4,67,68].
Some bacterial strains seems to specifically mediate their own translocation without collateral
translocation of other bacteria from the host digestive tract [12,69]. Many transient anatomical and
physiological changes that occur during pregnancy and lactation may favor an increased bacterial
translocation during such periods [1,62,70–72] and have been reviewed in [37].
At present, it is widely accepted that microbes are present in diverse organs and tissues previously
thought to be sterile environments, including tumors [12]. Oral administration of a probiotic
Bifidobacterium breve strain harboring a lux-expressing plasmid to mice bearing subcutaneous tumors
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led to its presence in tumors at levels similar to intravenous administration [12]. Similarly, another
probiotic strain (E. coli Nissle 1917) robustly colonized tumor tissue in rodent models of liver metastasis
after oral delivery but did not colonize healthy organs or fibrotic liver tissue [69]. The authors suggested
that oral delivery could lead to the preferential colonization of liver tumors by allowing probiotics to
follow physiological blood flow patterns, wherein the venous outflow from the gut is directed to the
liver via the hepatic portal vein. This phenomenon has been attributed to at least three different factors:
(a) suppressed immune surveillance within the tumor, (b) tumor vascularization, and (c) increased
availability of nutrients in the necrotic tumor core [73–76]. It has been proposed that the entry, survival,
and replication of bacteria in tumors depends on the vascularization and immune-privileged nature
of solid tumors, which may provide a suitable microenvironment for a small spectrum of bacterial
species [74]. The nutrient-rich environment may also play an important role since tumors can support
the growth of auxotrophic S. typhimurium strains [76–78]. Interestingly, the same factors are also
present in the mammalian glands during late pregnancy and may explain the selective tropism or
homing effect that the mammary gland seems to exert on some maternal bacterial species during this
life stage: (a) there is a physiological immunodepression state in order to tolerate the fetus; (b) as stated
above, there is a formidable angiogenesis process; and (c) pre-colostrum starts to fill the mammary
duct during the last third of pregnancy providing a rich nutrient environment for bacteria.
Further studies are required to elucidate the mechanisms by which some bacterial strains may
translocate physiologically in certain hosts or life stages. The existence of such bacterial oral-
and entero-mammary pathways would provide new opportunities for manipulating an altered
maternal-fetal microbiota, reducing the risk of preterm birth or infant diseases.
5. Conclusions
Human milk is one of the main sources for the vertical mother-to-infant transmission of bacteria
in early life. Although the origin of the bacteria naturally present in this biological fluid can be diverse,
the results of this study confirm that there may be a physiological translocation of certain bacterial
strains from the maternal digestive tract to the mammary gland and milk.
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